Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
Cowen Reiterates Market Perform on Keryx Biopharma (KERX) Following Announced Aurxyia Approval in EU
-
Notable Analyst Rating Changes 7/23: (EMC) (DWA) (UTX) Upgraded; (XOMA) (KERX) (HTZ) Downgraded
-
Cowen Downgrades Keryx Biopharmaceuticals (KERX) to Market Perform; Auryxia Adoption Likely To Miss
-
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
-
Streetinsider.com's Hot Lunchtime Reads 2/25: (DB) (KERX) (AKAM) (SCTY) (SPWR)
-
Keryx Biopharmaceuticals (KERX) Pressure on Script Data Creates a Buying Chance - Cowen
-
Keryx Biopharma (KERX) Prices 9.17M Common Offering at $12/Share
-
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
-
Cowen Starts Keryx Biopharmaceuticals (KERX) at Outperform
-
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
-
Notable 52-Week Highs and Lows of the Day 01/28: (KERX) (NFLX) (WM) High; (SCHS) (JOSB) (RBY) Low
-
Unusual 11 Mid-Day Movers 12/30: (MOSY) (CAK) (LEAP) Higher; (DCTH) (SYMX) (LEDS) Lower
-
Top 10 News Items 6/1-6/5: GM IS BANKRUPT; Jobs Report Comes in Much Better-Than-Expected; Equity Offerings Still All The Rage

